» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...

Which company's stock will reach a trillion-dollar ($1T) market cap next?
$Berkshire Hathaway-B (BRK.B.US)$ , $Eli Lilly and Co (LLY.US)$ , $Tesla (TSLA.US)$ , $Broadcom (AVGO.US)$

$Inovio Pharmaceuticals (INO.US)$Inovio Smallpox Vaccine Protects Against Monkeypox (2010)
https://www.drugdiscoverytrends.com/inovio-smallpox-vaccine-protects-against-monkeypox/

$Coinbase (COIN.US)$ How? Can anyone tell me...

$Taiwan Semiconductor (TSM.US)$ I been holding TSM for a while and it feels the same as BAC. if their peers trend up, they will rise abit but when peers trend down they lose more. Is this a good indicator of a good company but a bad stock? Hmmm…

$Arcturus Therapeutics (ARCT.US)$
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html

$Sea (SE.US)$ seems like it’s best to go into hibernation and reopen the moomoo app few months later

$DiDi Global (Delisted) (DIDI.US)$ what happens after didi delist?? do I panic sell now or what’s next?

The iPhone maker $Apple (AAPL.US)$ generates large revenues and free cash flows and will most certainly continue to do so for the foreseeable future. This, however, could already be priced in the company's stock, which makes it susceptible to a price consolidation or slight correction in the short term. This is even more so due to the post-pandemic hefty 2021 revenue increases, which the company is unlikely to sustain in the next year or two.
I have compiled some data from the company's past annual reports. I will go quickly through the existing financial situation of the company and then move on to more fun stuff.
Revenue and Net Income
Apple generates revenues from multiple flagship products and services, including iPhone and iPad sales, App Store, Apple Care services, and cloud storage, to name a few. iPhone sales are the major contributor to revenues, but recently the Other Products category, which includes such items as Apple Watch, Home Air Pods, Home accessories and other wearables, has picked up quite nicely. Apple product users are pretty much locked into the iOS ecosystem and unwilling to part with such products anytime soon. Short of the company successively releasing a few subquality devices, it is not likely Apple's loyal customers will abandon the company anytime soon. This, in turn, will ensure Apple's consistent revenue generation for many more years to come.
The operating margin is good at over 25%, considering the fierce competition in the tech sector, where margins are always being tested in order to gain market share.
Earnings have seen a sharp increase in 2021 after modest gains over the previous years. The earnings will likely pull back a bit, in line with the trend leading up to the pandemic. The dividend yield is relatively low when compared to many other tech giants.
Return on Equity, Return on Invested Capital, and Return on Assets
The same can be observed with the return on equity, invested capital, and assets. All these three metrics have seen a jump in the last year, with the return in equity being the highest.
The free cash flow per share is illustrated in the chart below. The growth is steady as the company can generate a lot of cash due to the popularity of its products.
Financial Health
Apple's debt to equity ratio is 1.73, which is a bit high. The company will need to make principal payments at an average of $10 billion annually until 2026 and over $64 billion annually after that. The total term debt value is $118 billion.
The current and quick ratios have been declining in the last two years, correlated with the increase in liabilities. The quick ratio is slightly concerning due to having a value below 1, and the current ratio is not healthy either.
Free Cash Flow Yield
The chart below shows the relationship between the price and the FCF yield trend. This is another important metric in that it provides a measurement of the stock valuation. The stock price trending upwards while the yields are heading lower indicates an unsustainable trend and a likely correction in the short term.
Share buybacks
Conclusion
I think Apple is a great company that will handsomely reward its shareholders in the long run, but it would probably be wise to apply a wait-and-see approach in the short term. Any dip in the range of $125-130 would be a good entry position. If, after a correction, it breaks above $160, that would be my signal to increase my position to take advantage of the next bull run. Until then, I will be on the sidelines waiting patiently.
Thank you for reading.